

while, clinicians and patients will need to consider the current findings of Chambers et al., along with other available evidence, and decide on an individual basis whether the risks associated with exposure to SSRIs outweigh the benefits of the therapy.

No potential conflict of interest relevant to this article was reported.

From the National Institute of Child Health and Human Development, Bethesda, Md.

1. Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. *J Pediatr* 2002;140:306-10.
2. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med* 2006;354:579-87.
3. FDA public health advisory: paroxetine. Washington, D.C.: Center for Drug Evaluation and Research, Food and Drug Administration, December 2005. (Accessed January 5, 2006, at <http://www.fda.gov/cder/drug/advisory/paroxetine200512.htm>.)
4. Health Canada advises of potential serious adverse effects of SSRIs and other antidepressants on newborns [advisory]. Ottawa: Health Canada, August 2004. (Accessed January 24, 2006, at http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/2004/2004_44_e.html.)
5. Hines RN, Adams J, Buck GM, et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of

fluoxetine. *Birth Defects Res B Dev Reprod Toxicol* 2004;71:193-280.

6. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. *JAMA* 2005;293:2372-83.
7. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. *Pediatrics* 2000;105:14-20.
8. Pediatrics Subcommittee of the Anti-Infective Drugs Advisory Committee. Summary minutes of the Pediatrics Subcommittee of the Anti-Infective Drugs Advisory Committee June 9, 2004. Washington, D.C.: Center for Drug Evaluation and Research, Food and Drug Administration, June 18, 2004. (Accessed January 19, 2006, at <http://www.fda.gov/ohrms/dockets/ac/04/minutes/2004-4050M1.pdf>.)
9. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. *Arch Pediatr Adolesc Med* 2004;158:312-6.
10. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. *N Engl J Med* 1996;335:1010-5.
11. Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. *Obstet Gynecol* 2004;103:698-709. [Erratum, *Obstet Gynecol* 2004;103:1344.]
12. Field T. Infants of depressed mothers. *Infant Behav Dev* 1995;18:1-13.
13. Mann JJ. The medical management of depression. *N Engl J Med* 2005;353:1819-34.

Copyright © 2006 Massachusetts Medical Society.

Expression of Concern: Sudbø J et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. *N Engl J Med* 2001;344:1270-8 and Sudbø J et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. *N Engl J Med* 2004;350:1405-13

Gregory D. Curfman, M.D., Stephen Morrissey, Ph.D., and Jeffrey M. Drazen, M.D.

In the issue of April 26, 2001, we published a study by Jon Sudbø et al.¹ Figure 3B and Figure 3C of that article, which purport to represent two different patients and stages of oral epithelial dysplasia, are in fact different magnifications of the same photomicrograph. Because the results of another study by Dr. Sudbø,² published in the issue of April 1, 2004, were derived from the same subjects followed through the same database, we have similar concerns. We have informed the

director of Dr. Sudbø's institution, the Radiumhospitalet in Oslo, Norway, and await the results of his investigation.

1. Sudbø J, Kildal W, Risberg B, et al. DNA Content as a Prognostic Marker in Patients with Oral Leukoplakia. *N Engl J Med* 2001;344:1270-8.
2. Sudbø J, Lippman SM, Lee JJ, et al. The Influence of Resection and Aneuploidy on Mortality in Oral Leukoplakia. *N Engl J Med* 2004;350:1405-13.

Copyright © 2006 Massachusetts Medical Society.